These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 25251804)
21. Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N. Vreede CL; Berkhout MC; Sprij AJ; Fokkens WJ; Heijerman HG J Cyst Fibros; 2015 May; 14(3):412-3. PubMed ID: 25169789 [TBL] [Abstract][Full Text] [Related]
22. Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis. Med Lett Drugs Ther; 2018 Oct; 60(1558):174-176. PubMed ID: 30335045 [No Abstract] [Full Text] [Related]
23. A safety evaluation of ivacaftor for the treatment of cystic fibrosis. McColley SA Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005 [TBL] [Abstract][Full Text] [Related]
24. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy. Hayes D; Long FR; McCoy KS; Sheikh SI Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273 [No Abstract] [Full Text] [Related]
25. The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D). Polenakovik HM; Sanville B J Cyst Fibros; 2013 Sep; 12(5):530-1. PubMed ID: 23313410 [TBL] [Abstract][Full Text] [Related]
26. Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation. Burghard MM; Berkers GG; Ghijsen SS; Hollander-Kraaijeveld FF; de Winter-de Groot KK; van der Ent CK; Heijerman HH; Takken TT; Hulzebos HE Pediatr Pulmonol; 2020 Jun; 55(6):1400-1405. PubMed ID: 32233113 [TBL] [Abstract][Full Text] [Related]
27. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. Bratcher PE; Rowe SM; Reeves G; Roberts T; Szul T; Harris WT; Tirouvanziam R; Gaggar A J Cyst Fibros; 2016 Jan; 15(1):67-73. PubMed ID: 25769931 [TBL] [Abstract][Full Text] [Related]
28. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation. Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139 [TBL] [Abstract][Full Text] [Related]
29. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation. Hebestreit H; Sauer-Heilborn A; Fischer R; Käding M; Mainz JG J Cyst Fibros; 2013 Dec; 12(6):599-603. PubMed ID: 23757359 [TBL] [Abstract][Full Text] [Related]
36. Improvement in bronchiectasis on CT imaging in a pediatric patient with cystic fibrosis on ivacaftor therapy. Hayes D; Long FR; McCoy KS; Sheikh SI Respiration; 2014; 88(4):345. PubMed ID: 25171465 [No Abstract] [Full Text] [Related]
37. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. Van Goor F; Yu H; Burton B; Hoffman BJ J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399 [TBL] [Abstract][Full Text] [Related]
38. Cystic fibrosis in an era of genomically guided therapy. Barrett PM; Alagely A; Topol EJ Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736 [TBL] [Abstract][Full Text] [Related]
39. A successful uncomplicated CF pregnancy while remaining on Ivacaftor. Kaminski R; Nazareth D J Cyst Fibros; 2016 Jan; 15(1):133-4. PubMed ID: 26698017 [No Abstract] [Full Text] [Related]
40. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]